PD-1/PD-L1
Les inhibiteurs de PD-1/PD-L1 sont des inhibiteurs de points de contrôle immunitaires qui bloquent l'interaction entre la protéine de mort cellulaire programmée 1 (PD-1) sur les cellules T et son ligand PD-L1 sur les cellules cancéreuses. Cette interaction supprime normalement la réponse immunitaire et permet aux cellules cancéreuses d'échapper à la détection immunitaire. En inhibant PD-1/PD-L1, ces inhibiteurs renforcent la capacité du système immunitaire à reconnaître et à détruire les cellules cancéreuses, induisant l'apoptose et la régression tumorale. Les inhibiteurs de PD-1/PD-L1 sont essentiels dans la recherche en immunothérapie et dans le traitement du cancer. Chez CymitQuimica, nous offrons une gamme d'inhibiteurs de PD-1/PD-L1 de haute qualité pour soutenir vos recherches en immuno-oncologie, apoptose et thérapie contre le cancer.
140 produits trouvés pour "PD-1/PD-L1"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
PD-L1/VISTA-IN-2
PD-L1/VISTA-IN-2 (Compound S8) is an orally active dual inhibitor targeting PD-L1 and VISTA, with an IC50 of 1.4 μM for PD-L1 and a KD of 2.1 μM for VISTA. This compound can activate the tumor immune microenvironment, exerting anticancer effects.Formule :C22H22N2O3Couleur et forme :SolidMasse moléculaire :362.42HX009
HX009 is a bispecific antibody that targets PD1 and CD47, though its binding to CD47 is attenuated. HX009 functions by blocking PD1/CD47 and can be utilized in research related to non-Hodgkin lymphoma (NHL).Couleur et forme :Odour LiquidPD-1/PD-L1-IN-9
CAS :PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction.Formule :C22H24N2O2Degré de pureté :99.92%Couleur et forme :SolidMasse moléculaire :348.44Ref: TM-T9651
1mg57,00€2mg85,00€5mg127,00€1mL*10mM (DMSO)140,00€10mg178,00€25mg298,00€50mg405,00€100mg535,00€500mg1.063,00€TPP-1 TFA
TPP-1 TFA is a high-affinity PD-L1 inhibitor (KD=95nM) that boosts T-cell function to curb tumor growth.Formule :C109H151F3N34O34S2Couleur et forme :SolidMasse moléculaire :2602.69PD-1/PD-L1-IN-48
PD-1/PD-L1-IN-48 (compound HD10) is an effective inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 3.1 nM. It plays a vital role in cancer research.Couleur et forme :Odour SolidHuman PD-L1 inhibitor I
CAS :Human PD-L1 inhibitor I, a peptide, blocks PD-L1/PD-1 interaction with 3.39 μM affinity.Formule :C110H152N26O32Couleur et forme :SolidMasse moléculaire :2350.576BMSpep-57
CAS :BMSpep-57: Macrocyclic peptide, inhibits PD-1/PD-L1, IC50=7.68 nM, binds PD-L1 (Kd=19 nM/MST, 19.88 nM/SPR), boosts T cell IL-2 in PBMCs.Formule :C89H126N24O19SCouleur et forme :SolidMasse moléculaire :1868.2Human PD-L1 inhibitor II
CAS :Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.Formule :C103H151N25O30Couleur et forme :SolidMasse moléculaire :2219.486GJ19
GJ19 is a PD-L1 inhibitor with an IC50 of 32.06 nM. It binds effectively to human and mouse PD-L1 proteins, exhibiting KD values of 171 nM and 290 nM, respectively. In a co-culture model of HepG2/hPD-L1 and Jurkat T/hPD-1 cells, GJ19 promotes HepG2 cell death in a concentration-dependent manner. In the B16-F10 melanoma mouse model, GJ19 demonstrates significant tumor growth inhibition. GJ19 is applicable in tumor immunotherapy research.Couleur et forme :Odour SolidPD-1/PD-L1-IN-51
PD-1/PD-L1-IN-51 (Compound III-4) is an inhibitor of PD-1/PD-L1 (IC50: hPD-L1 at 2.9 nM). It binds directly to PD-L1, blocking the interaction between PD-1 and PD-L1, and enhancing the release of IFN-γ. Additionally, PD-1/PD-L1-IN-51 exhibits antitumor activity.Couleur et forme :Odour SolidCamrelizumab
CAS :Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity and directed against PD-1.Camrelizumab binds PD-1 with a binding affinity of up
Degré de pureté :95% - 98.6%Couleur et forme :LiquidMasse moléculaire :143.7 kDaPD-L1-IN-5
PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor with an IC50 of 785.6 nM, demonstrating antitumor activity in vivo.PD-1/PD-L1-IN-52
PD-1/PD-L1-IN-52 (Compound Ⅲ-5) is an orally active inhibitor of PD-1/PD-L1 interaction, exhibiting an IC50 of 109.9 nM. It demonstrates antitumor activity in a C57BL/6 mouse model of MC38 colon carcinoma cells expressing human PD-1, achieving a tumor growth inhibition (TGI) rate of 49.6%.Couleur et forme :Odour SolidHuman membrane-bound PD-L1 polypeptide
CAS :Human membrane-bound PD-L1 polypeptide serves as an antigen for inducing the production of PD-L1 antibodies [1].Formule :C85H140N26O36SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :2134.24Human PD-L1 inhibitor III
CAS :Human PD-L1 inhibitor III is a human PD-L1 inhibitor.Formule :C97H155N29O29SCouleur et forme :SolidMasse moléculaire :2223.54PD-1/PD-L1-IN-39
PD-1/PD-L1-IN-39 (X 14) is an orally active PD-1/PD-L1 inhibitor with an IC50 value of 15.73 nM. It exhibits strong binding affinity to human and mouse PD-L1, with KD values of 14.62 and 392 nM, respectively. PD-1/PD-L1-IN-39 also demonstrates antitumor activity.Formule :C23H20ClFN2O3Masse moléculaire :426.11465PROTAC PD-L1 degrader-1
PROTACPD-L1 degrader-1 is a CRBN-based PD-L1-PROTAC degrader with significant PD-L1 protein degradation capacity. It demonstrates strong PD-L1 degradation activity in 4T1 cells, with a DC50 of 0.609 μM. This compound is applicable to breast cancer research.OPBP-1
OPBP-1 is a D-peptide developed through phage display screening, molecular docking, and molecular dynamics simulations. It exhibits high stability, strong antitumor activity, and oral bioavailability. OPBP-1 selectively binds to the PD-L1 protein, significantly blocking the interaction between PD-1 and PD-L1, which helps restore and enhance T lymphocyte function while reducing the proportion of myeloid-derived suppressor cells (MDSCs), counteracting tumor-induced immune evasion. OPBP-1 is applicable for research in cancer immunotherapy.Formule :C64H92N20O19SMasse moléculaire :1476.65683AUNP-12
CAS :AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.Formule :C142H226N40O48Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :3261.55Human PD-L1 inhibitor IV
CAS :PD-L1 inhibitor IV, a polypeptide, competitively blocks hPD-1 with a Kd of 1.38 μM, preventing hPD-1/hPD-L1 interaction.Formule :C80H113N25O27Couleur et forme :SolidMasse moléculaire :1856.932
